focus -WSS

focus

author：knowledge 2025-09-27 16:48:40 - browse：8

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Mass General Brigham physicians react to latest merger step

knowledge

WSS

Multiple sclerosis has subtypes with different best treatments: study

Testing GLP

CRISPR technology availability, affordability needs to be expanded

Oral obesity drug from Viking Therapeutics hits key early target

Covid silver lining: Unprecedented look at human immune system

Republican states more likely to report Covid vaccine side effects

hotspot

focus

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

With Wegovy coverage, Medicare patients may face high costs

Bright Health sells Medicare Advantage business to Molina

Bring on the sabbaticals for nurses

Walensky prepares to leave CDC — and Congress — behind

Overprescribed: High cost isn't America's only drug problem

Psychedelics group wrestles with new pharma identity

Yancopoulos of Regeneron works to expand Dupixent success

Heart attack and stroke risk calculators need revising

People with mental disorders often marry others with same

entertainment

Hundreds died while taking an arthritis drug, but nobody alerted patients

Insurer loopholes limit power of law against surprise medical bills

Scientific mystery highlights the blind spots in genomics databases

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

U.K. decision on ALS drug has neurologists, advocates up in arms

Researchers test human milk's ability to repair gut microbiome

focus

hotspot

knowledge

entertainment